Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non–MSI-H/non–dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results

Authors: O'Malley, David M. ^{a, ⁎}, Bariani, Giovani M. ^b, Cassier, Philippe A. ^c, Marabelle, Aurelien ^d, Hansen, Aaron R. ^e, Acosta, Ana De Jesus ^f, Miller, Wilson H., Jr ^g, Safra, Tamar ^h, Italiano, Antoine ^{i, j}, Mileshkin, Linda ^k, Yao, Lili ^l, Gozman, Alexander ^l, Jin, Fan ^l, Maio, Michele ^m

Source: In Gynecologic Oncology February 2025 193:130-135

PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade

Authors: Srour, Nivine, Villarreal, Oscar D., Hardikar, Swanand, Yu, Zhenbao, Preston, Samuel, Miller, Wilson H., Jr., Szewczyk, Magdelena M., Barsyte-Lovejoy, Dalia, Xu, Han, Chen, Taiping, del Rincón, Sonia V., Richard, Stéphane

Source: In Cell Reports 29 March 2022 38(13)

High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study

Authors: Elkrief, Arielle, Desilets, Antoine, Papneja, Neha, Cvetkovic, Lena, Groleau, Catherine, Lakehal, Yahia Abdelali, Shbat, Layla, Richard, Corentin, Malo, Julie, Belkaid, Wiam, Cook, Erin, Doucet, Stéphane, Tran, Thai Hoa, Jao, Kevin, Daaboul, Nathalie, Bhang, Eric, Loree, Jonathan M., Miller, Wilson H., Jr., Vinh, Donald C., Bouganim, Nathaniel, Batist, Gerald, Letendre, Caroline, Routy, Bertrand

Source: In European Journal of Cancer November 2020 139:181-187

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Authors: Marabelle, Aurélien ^*, Fakih, Marwan, Lopez, Juanita, Shah, Manisha, Shapira-Frommer, Ronnie, Nakagawa, Kazuhiko, Chung, Hyun Cheol, Kindler, Hedy L, Lopez-Martin, Jose A, Miller, Wilson H, Jr, Italiano, Antoine, Kao, Steven, Piha-Paul, Sarina A, Delord, Jean-Pierre, McWilliams, Robert R, Fabrizio, David A, Aurora-Garg, Deepti, Xu, Lei, Jin, Fan, Norwood, Kevin, Bang, Yung-Jue

Source: In The Lancet Oncology October 2020 21(10):1353-1365

Combined Inhibition of MNK Signaling and BET Proteins Reveals TGM2 as a Novel Vulnerability in Melanoma

Authors: Méant, Antoine ^{1, 2}, Moussa, Omar ^{1, 2}, Lebeau, Benjamin ^{1, 2, 3}, Gonçalves, Christophe ¹, Richard, Vincent R. ⁴, Cai, Feiyang ^{1, 2}, Prabhu, Sathyen A. ^{1, 2}, Langke, Marios ^{1, 2}, Guettler, Elizabeth M. ¹, Su, Jie ¹, Gagnon, Natascha ¹, Zahedi, Rene P. ^{4, 5}, Borchers, Christoph H. ^{4, 6}, Miller, Wilson H., Jr. ^{1, 2, 6}, del Rincón, Sonia V. ^{1, 2, 6, ∗}, Witcher, Michael ^{1, 2, 6, ∗}

Source: In Journal of Investigative Dermatology April 2025 145(4):979-984

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

Authors: Chung, Hyun Cheol, Piha-Paul, Sarina A., Lopez-Martin, Jose, Schellens, Jan H.M., Kao, Steven, Miller, Wilson H., Jr., Delord, Jean-Pierre, Gao, Bo, Planchard, David, Gottfried, Maya, Zer, Alona, Jalal, Shadia I., Penel, Nicolas, Mehnert, Janice M., Matos, Ignacio, Bennouna, Jaafar, Kim, Dong-Wan, Xu, Lei, Krishnan, Suba, Norwood, Kevin, Ott, Patrick A.

Source: In Journal of Thoracic Oncology April 2020 15(4):618-627

Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma

Authors: Petrella, Teresa M., Robert, Caroline, Richtig, Erika, Miller, Wilson H., Jr., Masucci, Giuseppe V., Walpole, Euan, Lebbe, Celeste, Steven, Neil, Middleton, Mark R., Hille, Darcy, Zhou, Wei, Ibrahim, Nageatte, Cebon, Jonathan

Source: In European Journal of Cancer November 2017 86:115-124

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis

Authors: Blank, Christian U., Larkin, James, Arance, Ana M., Hauschild, Axel, Queirolo, Paola, Del Vecchio, Michele, Ascierto, Paolo A., Krajsova, Ivana, Schachter, Jacob, Neyns, Bart, Garbe, Claus, Chiarion Sileni, Vanna, Mandalà, Mario, Gogas, Helen, Espinosa, Enrique, Hospers, Geke A.P., Miller, Wilson H., Jr., Robson, Susan, Makrutzki, Martina, Antic, Vladan, Brown, Michael P.

Source: In European Journal of Cancer July 2017 79:176-184

NPM and BRG1 Mediate Transcriptional Resistance to Retinoic Acid in Acute Promyelocytic Leukemia

Authors: Nichol, Jessica N., Galbraith, Matthew D., Kleinman, Claudia L., Espinosa, Joaquín M., Miller, Wilson H., Jr.

Source: In Cell Reports 29 March 2016 14(12):2938-2949

The Role of eIF4E in Response and Acquired Resistance to Vemurafenib in Melanoma

Authors: Zhan, Yao ¹, Dahabieh, Michael S. ¹, Rajakumar, Arjuna ¹, Dobocan, Monica C. ², M’Boutchou, Marie-Noël ², Goncalves, Christophe ², Lucy, Shiru L. ¹, Pettersson, Filippa ², Topisirovic, Ivan ^{1, 2}, van Kempen, Léon ^{1, 2}, del Rincón, Sonia V. ², Miller, Wilson H., Jr. ^{1, 2, *}

Source: In Journal of Investigative Dermatology May 2015 135(5):1368-1376

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Authors: Weber, Jeffrey S, D'Angelo, Sandra P, Minor, David, Hodi, F Stephen, Gutzmer, Ralf, Neyns, Bart, Hoeller, Christoph, Khushalani, Nikhil I, Miller, Wilson H, Jr, Lao, Christopher D, Linette, Gerald P, Thomas, Luc, Lorigan, Paul, Grossmann, Kenneth F, Hassel, Jessica C, Maio, Michele, Sznol, Mario, Ascierto, Paolo A, Mohr, Peter, Chmielowski, Bartosz, Bryce, Alan, Svane, Inge M, Grob, Jean-Jacques, Krackhardt, Angela M, Horak, Christine, Lambert, Alexandre, Yang, Arvin S, Larkin, James

Source: In The Lancet Oncology April 2015 16(4):375-384

The Novel Arsenical Darinaparsin Is Transported by Cystine Importing Systems

Authors: Garnier, Nicolas, Redstone, Geneviève G.J., Dahabieh, Michael S., Nichol, Jessica N., del Rincon, Sonia V., Gu, Yuxuan, Bohle, D. Scott, Sun, Yan, Conklin, Douglas S., Mann, Koren K., Miller, Wilson H., Jr. ^*

Source: In Molecular Pharmacology April 2014 85(4):576-585

Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study

Authors: Larkin, James, Del Vecchio, Michele, Ascierto, Paolo A, Krajsova, Ivana, Schachter, Jacob, Neyns, Bart, Espinosa, Enrique, Garbe, Claus, Sileni, Vanna Chiarion, Gogas, Helen, Miller, Wilson H, Jr, Mandalà, Mario, Hospers, Geke A P, Arance, Ana, Queirolo, Paola, Hauschild, Axel, Brown, Michael P, Mitchell, Lada, Veronese, Luisa, Blank, Christian U

Source: In Lancet Oncology April 2014 15(4):436-444

Triple A therapy: The molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide

Authors: Nichol, Jessica N., Garnier, Nicolas, Miller, Wilson H., Jr.

Source: In Best Practice & Research Clinical Haematology March 2014 27(1):19-31

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Authors: Hauschild, Axel, Grob, Jean-Jacques, Demidov, Lev V, Jouary, Thomas, Gutzmer, Ralf, Millward, Michael, Rutkowski, Piotr, Blank, Christian U, Miller, Wilson H, Jr, Kaempgen, Eckhart, Martín-Algarra, Salvador, Karaszewska, Boguslawa, Mauch, Cornelia, Chiarion-Sileni, Vanna, Martin, Anne-Marie, Swann, Suzanne, Haney, Patricia, Mirakhur, Beloo, Guckert, Mary E, Goodman, Vicki, Chapman, Paul B

Source: In The Lancet 28 July-3 August 2012 380(9839):358-365

Dual inhibition of the homologous recombinational repair and the nonhomologous end-joining repair pathways in chronic lymphocytic leukemia therapy

Authors: Amrein, Lilian, Davidson, David, Shawi, May, Petruccelli, Lucas A., Miller, Wilson H., Jr., Aloyz, Raquel, Panasci, Lawrence

Source: In Leukemia Research August 2011 35(8):1080-1086

Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study

Authors: Puts, Martine T.E., Monette, Johanne, Girre, Veronique, Pepe, Carmela, Monette, Michele, Assouline, Sarit, Panasci, Lawrence, Basik, Mark, Miller, Wilson H., Jr, Batist, Gerald, Wolfson, Christina, Bergman, Howard

Source: In Critical Reviews in Oncology and Hematology 2011 78(2):138-149

Oxalic acid excretion after intravenous ascorbic acid administration

Authors: Robitaille, Line, Mamer, Orval A., Miller, Wilson H., Jr., Levine, Mark, Assouline, Sarit, Melnychuk, David, Rousseau, Caroline, Hoffer, L. John

Source: In Metabolism February 2009 58(2):263-269

Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer

Authors: Eisen, Tim, Thatcher, Nick, Leyvraz, Serge, Miller, Wilson H., Jr., Couture, Felix, Lorigan, Paul, Lüthi, François, Small, David, Tanovic, Adnan, O’Brien, Mary

Source: In Lung Cancer 2009 64(1):60-65

Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: A phase II study

Authors: Power, Patti ^⁎, Stuart, Gavin, Oza, Amit, Provencher, D., Bentley, James R., Miller, Wilson H., Jr, Pouliot, Jean-François

Source: In Gynecologic Oncology 2009 114(3):410-414